AR115991A1 - EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN - Google Patents
EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓNInfo
- Publication number
- AR115991A1 AR115991A1 ARP190102374A ARP190102374A AR115991A1 AR 115991 A1 AR115991 A1 AR 115991A1 AR P190102374 A ARP190102374 A AR P190102374A AR P190102374 A ARP190102374 A AR P190102374A AR 115991 A1 AR115991 A1 AR 115991A1
- Authority
- AR
- Argentina
- Prior art keywords
- visual
- individual
- compound
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un método para tratar una condición ocular en un individuo que necesita ese tratamiento, el método comprende la administración al individuo de una cantidad terapéuticamente efectiva de un compuesto de la fórmula (1) o una sal suya farmacéuticamente aceptable, y en donde la condición ocular se selecciona de un grupo que consiste en presbicia, visión nocturna deficiente, deslumbramiento visual, destellos visuales, halos visuales y miopía nocturna. Reivindicación 41: Un compuesto de la fórmula (1) o una sal suya farmacéuticamente aceptable, en un método para tratar una condición ocular en un individuo que la necesita, el método comprende la administración al individuo de una cantidad terapéuticamente efectiva de el compuesto de la fórmula (1) o una sal suya farmacéuticamente aceptable, y en donde la condición ocular se selecciona de un grupo que consiste en presbicia, visión nocturna deficiente, deslumbramiento visual, destellos visuales, halos visuales y miopía nocturna.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720671P | 2018-08-21 | 2018-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115991A1 true AR115991A1 (es) | 2021-03-17 |
Family
ID=67841225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102374A AR115991A1 (es) | 2018-08-21 | 2019-08-21 | EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20210205273A1 (es) |
| EP (1) | EP3840750A1 (es) |
| JP (1) | JP2021534217A (es) |
| KR (1) | KR20210047323A (es) |
| CN (1) | CN112823003A (es) |
| AR (1) | AR115991A1 (es) |
| AU (1) | AU2019325486A1 (es) |
| BR (1) | BR112021003295A2 (es) |
| CA (1) | CA3110318A1 (es) |
| CL (1) | CL2021000440A1 (es) |
| CO (1) | CO2021003460A2 (es) |
| IL (1) | IL280990A (es) |
| MX (1) | MX2021002112A (es) |
| PH (1) | PH12021550372A1 (es) |
| SG (1) | SG11202101730SA (es) |
| TW (1) | TW202021584A (es) |
| WO (1) | WO2020041340A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210260041A1 (en) * | 2020-02-20 | 2021-08-26 | Allergan, Inc. | Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision |
| JP2024508811A (ja) | 2021-02-24 | 2024-02-28 | オキュラ セラピューティクス，インコーポレイテッド | 小管内デポーインサータ装置 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| KR20180117211A (ko) | 2010-01-22 | 2018-10-26 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| TWI722298B (zh) | 2013-03-15 | 2021-03-21 | 美商歐樂根公司 | 含有前列醯胺之眼內植入物 |
| CA2907881A1 (en) | 2013-03-27 | 2014-10-02 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| EP2981248B1 (en) | 2013-04-01 | 2020-09-02 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| WO2016168141A1 (en) | 2015-04-13 | 2016-10-20 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11077053B2 (en) * | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
-
2019
- 2019-08-20 AU AU2019325486A patent/AU2019325486A1/en active Pending
- 2019-08-20 JP JP2021510070A patent/JP2021534217A/ja active Pending
- 2019-08-20 MX MX2021002112A patent/MX2021002112A/es unknown
- 2019-08-20 BR BR112021003295-9A patent/BR112021003295A2/pt unknown
- 2019-08-20 CA CA3110318A patent/CA3110318A1/en active Pending
- 2019-08-20 TW TW108129699A patent/TW202021584A/zh unknown
- 2019-08-20 WO PCT/US2019/047305 patent/WO2020041340A1/en active Application Filing
- 2019-08-20 EP EP19762588.2A patent/EP3840750A1/en active Pending
- 2019-08-20 US US17/055,922 patent/US20210205273A1/en not_active Abandoned
- 2019-08-20 SG SG11202101730SA patent/SG11202101730SA/en unknown
- 2019-08-20 CN CN201980065608.3A patent/CN112823003A/zh active Pending
- 2019-08-20 KR KR1020217008132A patent/KR20210047323A/ko unknown
- 2019-08-21 AR ARP190102374A patent/AR115991A1/es unknown
-
2021
- 2021-02-21 IL IL280990A patent/IL280990A/en unknown
- 2021-02-22 CL CL2021000440A patent/CL2021000440A1/es unknown
- 2021-02-22 PH PH12021550372A patent/PH12021550372A1/en unknown
- 2021-03-17 CO CONC2021/0003460A patent/CO2021003460A2/es unknown
- 2021-06-30 US US17/364,470 patent/US20220160623A1/en not_active Abandoned
- 2021-10-29 US US17/452,963 patent/US20220288031A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021003460A2 (es) | 2021-04-08 |
| US20220160623A1 (en) | 2022-05-26 |
| US20210205273A1 (en) | 2021-07-08 |
| PH12021550372A1 (en) | 2021-11-29 |
| KR20210047323A (ko) | 2021-04-29 |
| CN112823003A (zh) | 2021-05-18 |
| WO2020041340A1 (en) | 2020-02-27 |
| CL2021000440A1 (es) | 2021-09-20 |
| BR112021003295A2 (pt) | 2021-05-18 |
| JP2021534217A (ja) | 2021-12-09 |
| TW202021584A (zh) | 2020-06-16 |
| EP3840750A1 (en) | 2021-06-30 |
| AU2019325486A1 (en) | 2021-03-25 |
| US20220288031A1 (en) | 2022-09-15 |
| IL280990A (en) | 2021-04-29 |
| CA3110318A1 (en) | 2020-02-27 |
| SG11202101730SA (en) | 2021-03-30 |
| MX2021002112A (es) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014563A2 (es) | Uso de clorhidrato de pilocarpina para el tratamiento de condiciones oculares | |
| CO2021004966A2 (es) | Inhibidores de la proteína tirosina fosfatasa | |
| CL2017002526A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015) | |
| PE20212077A1 (es) | Nuevos compuestos sulfonamida de carboxamida | |
| CO2020009225A2 (es) | Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco | |
| AR115991A1 (es) | EL USO DE AGONISTAS DE LOS RECEPTORES a2 ADRENÉRGICOS PARA MEJORAR LA VISIÓN | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| RU2013142602A (ru) | Композиции и способы для нехирургического лечения птоза | |
| ATE191143T1 (de) | Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| WO2019195761A3 (en) | Pharmacological agents for treating ocular diseases | |
| EA202090594A1 (ru) | Способы, системы и композиции для поддержания функционирования дренажных подушек, связанных с инородными телами | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| AR119122A2 (es) | Soluciones intracamerales antiinflamatorias y midriáticas para la inhibición de las afecciones inflamatorias oculares postoperatorias | |
| MX2021007161A (es) | Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia. | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| ZA202108950B (en) | Oxymetazoline compositions and methods for treating ocular disorders | |
| EA201690532A1 (ru) | Не содержащий консерванта офтальмологический фармацевтический состав | |
| ES2421405T3 (es) | Composiciones que comprenden un agonista del receptor de glucocorticoides disociado para tratar o controlar una inflamación del segmento anterior | |
| MX2020009132A (es) | Composiciones farmaceuticas que comprenden nebivolol. | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| AR106691A1 (es) | Formulaciones oftálmicas de escualamina | |
| MX2022010317A (es) | Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision. | |
| RU2015133365A (ru) | Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно |